Ondine Biomedical’s Steriwave nasal photodisinfection technology
has been shortlisted in the biomedical category of the 2024
international society for optics and photonics SPIE Prism Awards.
Ondine’s nasal photodisinfection technology, which has been
significantly reducing hospital acquired infections, uses a
combination of a photosensitive agent and red laser light to
eliminate bacteria, viruses, and fungi in the nose in minutes
without generating resistance.
Nasal photodisinfection is a painless, five-minute treatment
that uses a patented photosensitive agent and specific, non-UV
light to trigger photochemical reactions that produce reactive
oxygen species. These reactive oxygen species are lethal to a broad
spectrum of microbes, including bacteria, fungi, and viruses.
Ondine CEO, Carolyn Cross, comments, “It is fantastic to see
photodisinfection receiving wider recognition as a technology that
will be transformative for the future of healthcare. As the tide of
antimicrobial resistance continues to rise, we are fast approaching
a reality where a simple infection could be deadly. Our nasal
photodisinfection technology represents a new way of combatting
infections and, crucially, unlike antibiotics, it does not develop
resistance.”
Photodisinfection has been shown to be highly effective against
antibiotic-resistant bacteria, including extensively drug-resistant
strains, without showing any resistance formation. This makes
photodisinfection an exciting prospect for combatting rising rates
of antimicrobial resistance (AMR). Antimicrobial resistance (AMR)
remains a major public health concern, causing 1.27 million deaths
in 2019.i The AMR death rate is projected to rise to 10 million
globally by 2050.ii
Nasal photodisinfection is also widely used in hospitals across
Canada, as well as in Europe and Mexico, to prevent
healthcare-associated infections (HAIs) following surgery. Surgical
site infections (SSIs) are the most common of HAIs, and are a huge
burden on both healthcare systems and patients, with the estimated
cost of a prosthetic hip or knee infection costing up to
$100,000.iii
In hospital settings, pre-surgical use of Steriwave has resulted
in significant improvement in post-surgical outcomes including
lower rates of infection, reduced patient length of stay, fewer
readmissions, lower rates of antibiotic prescribing and significant
cost savings.iv,v,vi
Other applications for Ondine’s photodisinfection technology
include the treatment of chronic rhinosinusitis, decolonization of
burns and wounds, and disinfection of endotracheal tubes to reduce
the incidence of ventilator-associated pneumonia. Ondine has also
completed a proof-of-concept study which showed that
photodisinfection effectively eliminated pathogens commonly found
on hard surfaces in meat processing facilities, as well as those
directly located on fresh-cut chicken, beef, and pork meat.vii
The SPIE Prism Awards, run by SPIE the international society for
optics and photonics, recognize industrial innovation in photonics.
SPIE CEO Kent Rochford said, “the Prism Awards recognize the impact
that optics and photonics technologies and products have on our
lives. The optics and photonics industry plays a major role in
making the world a better place, and we always appreciate the
opportunity to acknowledge the scientists, engineers, and companies
that improve our lives in extraordinary ways. I’m looking forward
to congratulating all the finalists and winners at our celebration
at Photonics West in January.”
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Products beyond nasal photodisinfection include therapies for a
variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
___________________________
i
https://www.ox.ac.uk/news/2022-01-20-estimated-12-million-people-died-2019-antibiotic-resistant-bacterial-infections
ii “O’Neill Review into Antibiotic
Resistance”
https://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf
iii Rennert-May ED, Conly J, Smith S, et
al. The cost of managing complex surgical site infections following
primary hip and knee arthroplasty: A population-based cohort study
in Alberta, Canada. Infection Control & Hospital Epidemiology.
2018;39(10):1183-1188. doi:10.1017/ice.2018.199
iv Banaszek D, Inglis T, Tamir Ailon T,
Charest-Morin R, Dea N, Fisher C, Kwon B, Paquette S, Street J. The
efficacy and cost-effectiveness of photodynamic therapy in
prevention of surgical site infection. The Spine Journal, Volume
19, Issue 9, Supplement, 2019, Page S138.
v
https://www.londonstockexchange.com/news-article/OBI/ottawa-hospital-presents-steriwave-study-results/15860312
vi Bryce E, Wong T, Forrester L, et al.
Nasal photodisinfection and chlorhexidine wipes decrease surgical
site infections: a historical control study and propensity analysis
[published correction appears in J Hosp Infect. 2015 Sep;91(1):93].
J Hosp Infect. 2014;88(2):89-95. doi:10.1016/j.jhin.2014.06.017
vii
https://ondinebio.com/media/webinar-photodisinfection-for-food-safety/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113412727/en/
Vane Percy & Roberts (Media Contact) Simon Vane
Percy, Amanda Bernard +44 (0)77 1000 5910
Ondine Biomedical (LSE:OBI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ondine Biomedical (LSE:OBI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024